Abbott feels sting of shrinking DES (drug-eluting stent) market; cuts 1,200 jobs
This article was originally published in Clinica
Another big hitter has buckled under the pressures of a weakening drug-eluting stent (DES) market, with Abbott revealing on Tuesday (December 5) it was axing 1,200 jobs at two facilities that manufacture vascular products.
You may also be interested in...
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.